Third Arc Bio vs IBM

Side-by-side comparison of AI visibility scores, market position, and capabilities

IBM leads in AI visibility (80 vs 25)

Third Arc Bio

EmergingBioTech

Multifunctional Antibodies (T Cell Engagers)

Raised $52M Series A extension (Feb 2026) from a16z as new investor — total $217M. ARC101 (bispecific T cell engager, CLDN6+) in Phase 1 solid tumors. Platform spans oncology and autoimmune.

AI VisibilityBeta
Overall Score
D25
Category Rank
#1 of 1
AI Consensus
55%
Trend
up
Per Platform
ChatGPT
31
Perplexity
33
Gemini
35

About

Third Arc Bio raised a $52 million Series A extension in February 2026 with Andreessen Horowitz as a new investor, building on its prior $165 million Series A to reach $217 million in total financing. The company develops multifunctional antibodies — protein therapeutics that combine multiple mechanisms of action in a single molecule — with its lead program ARC101 being a bispecific T cell engager targeting CLDN6 in solid tumors, currently in Phase 1 clinical trials.

Full profile

IBM

LeaderEnterprise Software

General

Armonk NY hybrid cloud and enterprise AI (NYSE: IBM) at $62.8B revenue; $6B+ generative AI bookings, record $12.7B free cash flow 2024, DataStax acquisition for watsonx vector database competing with Microsoft Azure for enterprise AI.

AI VisibilityBeta
Overall Score
A80
Category Rank
#56 of 1158
AI Consensus
67%
Trend
up
Per Platform
ChatGPT
74
Perplexity
71
Gemini
84

About

International Business Machines Corporation (IBM) is an Armonk, New York-based global technology and consulting company — publicly traded on the New York Stock Exchange (NYSE: IBM) as an S&P 500 component — providing hybrid cloud infrastructure, artificial intelligence software, and enterprise IT consulting through approximately 270,300 employees in 170 countries with $62.8 billion in annual revenue. Founded on June 16, 1911, as Computing-Tabulating-Recording Company through a merger orchestrated by financier Charles Ranlett Flint, renamed IBM in 1924 under Thomas Watson Sr., IBM has undergone multiple strategic transformations over its 110+ year history: building the System/360 mainframe platform (1964), launching the IBM PC (1981), selling the PC division to Lenovo (2005, $1.75B), and completing the $34 billion Red Hat acquisition (2019) that repositioned IBM as a hybrid cloud platform company. CEO Arvind Krishna (appointed April 2020) has focused IBM's strategy on three areas: hybrid cloud (powered by Red Hat OpenShift, the enterprise Kubernetes platform), AI (the watsonx platform for enterprise AI model development and deployment), and enterprise consulting. Under Krishna, IBM recorded $12.7 billion in free cash flow in 2024 (a company record), surpassed $6 billion in generative AI bookings since June 2023, and saw the stock price double — trading at all-time highs through 2024-2025. IBM announced the DataStax acquisition in 2025 to deepen watsonx's data layer with AstraDB (vector database for AI applications), DataStax Enterprise (Apache Cassandra), and Langflow (low-code AI agent development).

Full profile

AI Visibility Head-to-Head

25
Overall Score
80
#1
Category Rank
#56
55
AI Consensus
67
up
Trend
up
31
ChatGPT
74
33
Perplexity
71
35
Gemini
84
22
Claude
74
18
Grok
81

Capabilities & Ecosystem

Capabilities

Only Third Arc Bio
Multifunctional Antibodies (T Cell Engagers)
IBM is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.